Top

Published in:

Open Access 01-12-2013 | Review Article

Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells

Authors: Piotr Trzonkowski, Anna Dukat-Mazurek, Maria Bieniaszewska, Natalia Marek-Trzonkowska, Anita Dobyszuk, Jolanta Juścińska, Magdalena Dutka, Jolanta Myśliwska, Andrzej Hellmann

Published in: BioDrugs | Issue 6/2013

Abstract

A significant body of evidence suggests that treatment with naturally occurring CD4⁺CD25⁺ T regulatory cells (Tregs) is an appropriate therapy for graft-versus-host disease (GvHD). GvHD is a major complication of bone marrow transplantation in which the transplanted immune system recognizes recipient tissues as a non-self and destroys them. In many cases, this condition significantly deteriorates the quality of life of the affected patients. It is also one of the most important causes of death after bone marrow transplantation. Tregs constitute a population responsible for dominant tolerance to self-tissues in the immune system. These cells prevent autoimmune and allergic reactions and decrease the risk of rejection of allotransplants. For these reasons, Tregs are considered as a cellular drug in GvHD. The results of the first clinical trials with these cells are already available. In this review we present important experimental facts which led to the clinical use of Tregs. We then critically evaluate specific requirements for Treg therapy in GvHD and therapies with Tregs currently under clinical investigation, including our experience and future perspectives on this kind of cellular treatment.

Billingham RE. The biology of graft-versus-host reactions. Harvey Lec. 1966;62:21–40.

Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K, Altman JD, Ahmed R. Estimating the precursor frequency of naive antigen-specifi c CD8 T cells. J Exp Med. 2002;195:657–64.PubMedCrossRef

Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood. 1991;77(1):182–94.PubMed

Sprent J, Schaefer M, Korngold R. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD. J Immunol. 1990;144(8):2946–54.PubMed

Mowat AM, Sprent J. Induction of intestinal graft-versus-host reactions across mutant major histocompatibility antigens by T lymphocyte subsets in mice. Transplantation. 1989;47(5):857–63.PubMedCrossRef

McGuinness UM, Baines MG. Augmented natural killer cell activity during neonatal graft-versus-host disease is of predominantly donor origin. Immunobiology. 1989;180(1):101–5.PubMedCrossRef

Ferrara JL, Guillen FJ, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation. 1989;47(1):50–4.PubMedCrossRef

Trzonkowski P, Zaucha JM, Mysliwska J, Balon J, Szmit E, Halaburda K, Bieniaszewska M, Mlotkowska M, Hellmann A, Mysliwski A. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. Med Oncol. 2004;21(1):81–94.PubMedCrossRef

Korngold R, Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165(6):1552–64.PubMedCrossRef

10.

Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood. 1994;83(2):600–9.PubMed

11.

Knobloch C, Dennert G. Loss of F1 hybrid resistance to bone marrow grafts after injection of parental lymphocytes. Demonstration of parental anti-F1 T killer cells and general immunosuppression in the host. Transplantation. 1988;45(1):175–83.PubMedCrossRef

12.

Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204–13.PubMed

13.

Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.PubMedCrossRef

14.

Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, Ferrara JL, Teshima T. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8.PubMed

15.

Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–47.PubMedCrossRef

16.

Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3⁺ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500.PubMedCrossRef

17.

Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, Huehn J, Ganser A, Förster R, Prinz I. Alloantigen-specific de novo-induced Foxp3⁺ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol. 2009;39(11):3091–6.PubMedCrossRef

18.

Edinger M, Hoffmann P. Regulatory T cells for the prevention of graft-versus-host disease: professionals defeat amateurs. Eur J Immunol. 2009;39(11):2966–8.PubMedCrossRef

19.

Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol. 1998;10:371–8.PubMedCrossRef

20.

Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L. Origin and T cell receptor diversity of Foxp3⁺CD4⁺CD25⁺ T cells. Immunity. 2006;25:249–59.PubMedCrossRef

21.

Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006;212:131–48.PubMedCrossRef

22.

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303–10.PubMedCrossRef

23.

Karim M, Feng G, Wood KJ, Bushell AR. CD25⁺CD4⁺ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood. 2005;105(12):4871–7.PubMedCrossRef

24.

Stassen M, Fondel S, Bopp T, Richter C, Muller C, Kubach J, Becker C, Knop J, Enk AH, Schmitt S, Schmitt E, Jonuleit H. Human CD25⁺ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4⁺ T helper cells. Eur J Immunol. 2004;34(5):1303–11.PubMedCrossRef

25.

Marski M, Kandula S, Turner JR, Abraham C. CD18 is required for optimal development and function of CD4⁺CD25⁺ T regulatory cells. J. Immunol. 2005;175(12):7889–97.PubMed

26.

Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 1992;176:1595–9.PubMedCrossRef

27.

Read S, Malmstrom V, Powrie F. CTLA4 plays an essential role in the function of CD25⁺CD4⁺ regulatory cells that control intestinal inflammation. J Exp Med. 2000;192(2):295–302.PubMedCrossRef

28.

Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12(1):210–7.PubMedCrossRef

29.

Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, Storb R, Sandmaier BM. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy. 2011;13(10):1269–80.PubMedCrossRef

30.

Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD4⁺CD25⁺ T regulatory cells inhibit cytotoxic activity of T CD8⁺ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004;112(3):258–67.PubMedCrossRef

31.

Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L. CD4⁺CD25⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075–85.PubMedCrossRef

32.

Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21(4):589–601.PubMedCrossRef

33.

Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4⁺CD25⁺ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174(4):1783–6.PubMed

34.

Bazhin AV, Kahnert S, Kimpfler S, Schadendorf D, Umansky V. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4⁺ T cells. Mol Immunol. 2010;47(4):678–84.PubMedCrossRef

35.

Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5’-adenosine monophosphate to adenosine. J Immunol. 2006;177(10):6780–6.PubMed

36.

Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. Nat Immunol. 2007;8(12):1353–62.PubMedCrossRef

37.

Yu A, Malek TR. Selective availability of IL-2 is a major determinant controlling the production of CD4⁺CD25⁺Foxp3⁺ T regulatory cells. J Immunol. 2006;177(8):5115–21.PubMed

38.

Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055–66.PubMedCrossRef

39.

Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43.

40.

Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4⁺CD25⁺Foxp3⁺ regulatory T cells. Blood. 2011;118(8):2342–50.PubMedCrossRef

41.

Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401–6.PubMedCrossRef

42.

Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, van Meerwijk JP. Prevention of acute and chronic allograft rejection with CD4⁺CD25⁺Foxp3⁺ regulatory T lymphocytes. Nat Med. 2008;14(1):88–92.PubMedCrossRef

43.

Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–99.PubMedCrossRef

44.

Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, Negrin RS, Fathman CG, Strober S. Only the CD62L⁺ subpopulation of CD4⁺CD25⁺ regulatory T cells protects from lethal acute GVHD. Blood. 2005;105(5):2220–6.PubMedCrossRef

45.

Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Grégoire S, Bonyhadi M, Klatzmann D, Salomon BL, Cohen JL. Ex vivo-expanded CD4⁺CD25⁺ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol. 2006;176(2):1266–73.PubMed

46.

Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, Cohen JL. Recipient-type specific CD4⁺CD25⁺ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688–96.PubMed

47.

MiltenyiBiotec. Clinical applications. Immunotherapy. 2012. https://www.miltenyibiotec.com/en/Clinical-applications/Immunotherapy/Treg-cells.aspx. Accessed 25 Jun 2013.

48.

BDBioscience. Regulatory T cells: essential regulators of the immune system. BD Biosci News Lett. 2009; ISBN: 23-10562-00.

49.

Trzonkowski P, Myśliwska J, Pawelec G, Myśliwski A. From bench to bedside and back—the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology. 2009;10(1):83–94.PubMedCrossRef

50.

Trzonkowski P, Szmit E, Mysliwska J, Mysliwski A. CD4⁺CD25⁺ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans: impact of immunosenescence. Clin Immunol. 2006;119(3):307–16.PubMedCrossRef

51.

Trzonkowski P, Debska-Slizień A, Jankowska M, Wardowska A, Carvalho-Gaspar M, Hak Ł, Moszkowska G, Bzoma B, Mills N, Wood KJ, Myśliwska J, Rutkowski B. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4⁺ T-cells. Mech Ageing Dev. 2010;131(2):96–104.PubMedCrossRef

52.

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz MA, Witkowski P, Mlynarski W, Balcerska A, Mysliwska J, Trzonkowski P. Administration of CD4⁺CD25^highCD127-regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012;35(9):1817–20.PubMedCrossRef

53.

Marek-Trzonkowska N, Myśliwec M, Siebert J, Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes. 2013. doi:10.1111/pedi.12029.PubMed

54.

Trzonkowski P, Szaryńska M, Myśliwska J, Myśliwski A. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A. 2009;75(3):175–88.PubMed

55.

Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orsó E, Andreesen R, Holler E, Edinger M. Isolation of CD4⁺CD25⁺ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2006;12(3):267–74.PubMedCrossRef

56.

Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, Porter SB. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood. 2004;104(2):453–6.PubMedCrossRef

57.

Milward K, Issa F, Hester J, Figueroa-Tentori D, Madrigal A, Wood KJ. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation. 2013;95(1):85–93.PubMedCrossRef

58.

Gołąb K, Krzystyniak A, Marek-Trzonkowska N, Misawa R, Wang LJ, Wang X, Cochet O, Tibudan M, Langa P, Millis JM, Trzonkowski P, Witkowski P. Impact of culture medium on CD4⁺CD25^highCD127^low/neg Treg expansion for the purpose of clinical application. Int Immunopharmacol. 2013. doi:S1567-5769(13)00058-1.

59.

Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, Hellmann A, Trzonkowski P. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. 2011;11–12:1747–58.CrossRef

60.

Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;18(3):83ra41.

61.

Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4⁺CD25⁺FoxP3⁺ regulatory T cells. Blood. 2005;105(12):4743–8.PubMedCrossRef

62.

Grzanka J, Leveson-Gower D, Golab K, Wang XJ, Marek-Trzonkowska N, Krzystyniak A, Wardowska A, Mills JM, Trzonkowski P, Witkowski P. FoxP3, Helios, and SATB1: roles and relationships in regulatory T cells. Int Immunopharmacol. 2013. doi:S1567-5769(13)00046-5.

63.

Piccirillo CA, Shevach EM. Control of CD8⁺ T cell activation by CD4⁺CD25⁺ immunoregulatory cells. J Immunol. 2001;167:1137–40.PubMed

64.

Marek N, Krzystyniak A, Ergenc I, Cochet O, Misawa R, Wang LJ, Gołąb K, Wang X, Kilimnik G, Hara M, Kizilel S, Trzonkowski P, Millis JM, Witkowski P. Coating human pancreatic islets with CD4(+)CD25(high)CD127(−) regulatory T cells as a novel approach for the local immunoprotection. Ann Surg. 2011;254(3):512–8.PubMedCrossRef

65.

Canavan JB, Afzali B, Scottà C, Fazekasova H, Edozie FC, Macdonald TT, Hernandez-Fuentes MP, Lombardi G, Lord GM. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood. 2012;119(8):57–66.CrossRef

66.

Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4⁺CD25⁺CD127^- T regulatory cells. Clin Immunol. 2009;133(1):22–6.PubMedCrossRef

67.

Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8.PubMedCrossRef

68.

Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–70.PubMedCrossRef

69.

Komanduri KV, Champlin RE. Can Treg therapy prevent GVHD? Blood. 2011;117(3):751–2.PubMedCrossRef

70.

Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol. 2011;23:679–84.PubMedCrossRef

71.

Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–28.PubMedCrossRef

72.

Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013. doi:S1567-5769(13)00043-X.

73.

Wang XJ, Leveson-Gower D, Golab K, Wang LJ, Marek-Trzonkowska N, Krzystyniak A, Wardowska A, Trzonkowski P, Witkowski P. Influence of pharmacological immunomodulatory agents on CD4⁺CD25^highFoxP3⁺ T regulatory cells in humans. Int Immunopharmacol. 2013. doi:S1567-5769(13)00057-X.

Title: Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells
Authors: Piotr Trzonkowski
Anna Dukat-Mazurek
Maria Bieniaszewska
Natalia Marek-Trzonkowska
Anita Dobyszuk
Jolanta Juścińska
Magdalena Dutka
Jolanta Myśliwska
Andrzej Hellmann
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 6/2013
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-013-0050-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Alpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies

Acknowledgement to Referees

Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example

Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment

Therapeutic Potential of Targeting Interleukin 5 in Asthma

Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents